We analyzed the results of a three or more drug combination as treatment for moderate or severe cGVHD developing after transplantation for thalassemia, in 45 patients with median age of 11 (range 2-26) years. Eighteen patients received a three drug regimen with cyclosporine (CsA), methylprednisolone (MP) and azathioprine (AZ) as first line therapy, 16 patients received this regimen as salvage therapy and 11 patients were given a four or five drug regimen with CsA, MP, AZ, cyclophosphamide (CY) and/or methotrexate (MTX) mainly as salvage therapy. The overall complete response (CR) rate was 77.3%, with 94% of CR in patients receiving the three drug regimen as first line, 88% in patients receiving it as salvage therapy and 36.6% in patients given the four or five drug regimen. The probability of CR in patients given the three drug regimen as first or salvage therapy or the four/five drug regimen was 89%, 53% and 30%, while the probability of survival was 89%, 65% and 58%, respectively. The incidence of treatment failure was low in our patients. Patients treated with the three drug regimen as first line therapy had less treatment-related complications than patients receiving this regimen as salvage therapy or patients given the four or five drug regimen. The main causes of treatment-related mortality (20%) were infectious complications. This retrospective study showed that a three or more drug combination is safe and effective for treatment of moderate or severe cGVHD at least in younger patients. Bone Marrow Transplantation (2001) 27, 45-51. Keywords: chronic graft-versus-host disease; bone marrow transplantation; thalassemia; multiagent immunosuppressive treatment Chronic graft-versus-host disease (cGVHD) is the most common late complication of allogeneic hematopoietic stem cell transplantation and its associated immunodeficiency and infection are major causes of morbidity and mortality following transplant. With the increasing number of allogeneic matched, mismatched and unrelated bone
marrow as well as peripheral blood stem cell transplantations, the number of patients with cGVHD continues to grow. The incidence of cGVHD after related matched or unrelated marrow and peripheral blood stem cell transplantation is 27-50%, [1] [2] [3] 42-72% 4,5 and 54-57%, 6, 7 respectively, with mortality occurring in 20% to 40% of affected patients despite aggressive treatment. 8 Progressive presentation from acute GVHD, liver dysfunction, lichenoid histology or concomitant thrombocytopenia at cGVHD onset have been found to carry a poor prognosis. 8, 9 Currently, corticosteroids alone or in combination with cyclosporine (CsA) remain the treatment of choice for established cGVHD. Although such conventional therapy has achieved complete responses in approximately 50% of patients, 10 the disease remains barely controllable in most patients. Over the past decade attempts to improve survival have led to the evaluation of alternative approaches for treatment of cGVHD with varying degrees of success. 11 However, it is difficult to define the role of these alternative therapies in the treatment of cGVHD as they were mostly given as salvage therapy along with conventional immunosuppressive medications. Clinical trials must be performed earlier in the course of the disease to establish the role of these drugs in the treatment of cGVHD.
In this retrospective study we have analyzed the results of treatment of extensive cGVHD with overall severity varying from moderate to severe using well known drugs such as CsA, methylprednisolone, azathioprine, cyclophosphamide or methotrexate in different combinations. To our knowledge there are no published data on the safety and the efficacy of a three or more aforementioned drug combination in patients with moderate or severe cGVHD. Therefore the objectives of this study were to evaluate: (1) the safety of long-term three or more immunosuppressive drug combinations, and (2) the efficacy of such treatment for moderate or severe cGVHD.
Materials and methods

Patients
Forty-five patients who received bone marrow transplants for thalassemia and had developed either moderate or severe cGVHD between January 1986 and May 1997 were enrolled into this study. One patient was not evaluable as death occurred 2 months after starting the treatment. Clinical characteristics of the 45 patients are shown in Table 1 . Three factors such as hepatomegaly more than 2 cm below costal margin, the presence of liver fibrosis on liver biopsy and irregular chelation history before transplant have been found to adversely influence the outcome of transplantation. On the basis of these factors patients were categorized into three classes of risk. Class 1 patients had none of these factors, class 2 patients had one or two factors and class 3 patients had all three adverse factors. 1 The preparative regimens varied according to class of risk and have been reported elsewhere; 1,12,13 they included busulfan 14 mg/kg and cyclophosphamide (CY) 200 mg/kg for class 1 and class 2 patients and busulfan 14/16 mg/kg and CY 120/160 mg/kg for class 3 patients. Only two patients in this study received methotrexate (MTX) for GVHD prophylaxis while the remaining patients were given CsA plus methylprednisolone (MP) (for class 1 and class 2 patients) or CsA, short courses of MTX and MP (for class 3 patients). Patients were scheduled to continue CsA prophylaxis until day 365. All but three patients were on tapering CsA prophylaxis when they developed cGVHD. In 42 patients the donors were HLA-identical siblings and in three patients HLA phenotypically identical parents.
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Assessment of cGVHD and grading
The diagnosis of cGVHD was made according to standard clinical criteria and confirmed histologically 3 except in cases of mouth or lung involvement. Progressive onset of cGVHD developed as a direct extension of acute GVHD, quiescent cGVHD occurred following resolution of acute GVHD and de novo cGVHD was not preceded by acute GVHD. Chronic GVHD is categorized as either limited (localized skin and/or hepatic involvement) or extensive (diffuse skin and/or multi organ involvement). 3 According to this grading scheme patients with limited organ involvement have a favorable outcome without treatment, while patients with extensive cGVHD always have a less favorable prognosis. As the severity of disease manifestations in patients with extensive cGVHD ranges from mild to severe changes, in addition to the Seattle scheme, we used a grading scheme according to overall severity of cGVHD which, we believe, is more practical for clinical purposes. According to this scheme patients were categorized as having mild, moderate or severe cGVHD. Patients with either localized or extensive cGVHD can have a mild, moderate or severe form of disease. Mild cGVHD is characterized by minor symptoms (insidious hyperpigmentation or parafollicular papules of the skin; white lacy reticular striae on the buccal surfaces or oral sensitivity to acidic or spicy foods; slight ocular dryness or episodic irritation; mild cholestatic abnormalities in the liver; chronic nausea and vomiting; and others) with Karnofsky performance score (KS) or Lansky play-performance score (LS) of 100-90%. Patients with moderate cGVHD have moderate manifestations of disease (erythematous rash or desquamation; mucositis with plaques on the buccal surface and tongue; dry eyes, burning or conjunctivitis; moderate liver dysfunction; chronic diarrhea or weight loss; marked obstructive abnormalities on pulmonary function testing and others) with KS or LS of 80-70%. Patients with severe cGVHD have severe changes of impaired organs (generalized scleroderma with joint contractures; oral mucositis with ulcers or dry atrophic mucosal surfaces; malabsorption with severe weight loss; corneal erosions with or without loss of sight; severe liver dysfunction; bronchiolitis obliterans with severe respiratory insufficiency and others) with KS or LS of Ͻ70%. The activity status of the patient according to KS was evaluated as: 100% -normal; 90% -symptomatic but able to carry on normal activity without special care; 80% -symptomatic requiring effort to perform normal activity; 70% -unable to carry on normal activity; 60% -requiring occasional assistance; 50% -requiring considerable assistance and frequent medical care; 40% -disabled and requires special care; 30% -severely disabled with hospitalization indicated; 20% -critical condition; 10% -moribund. According to LS the patient's activity status was as follows: 100% -fully active; 90% -minor restriction in physically strenuous play; 80% -restriction in strenuous play but active; 70% -greater restrictions in active play; 60% -limited active play with assistance; 50% -considerable assistance required for any active play, but fully able to engage in quiet play; 40% -able to initiate quiet activities; 30% -needs considerable assistance for quiet activity; 20% -limited to very passive activity; 10% -completely disabled, not even passive play. In patients with multiorgan involvement the overall severity was based on the organ with the maximum grade of impairment. Forty-four patients had sclerodermatous changes and one patient had lichenoid changes on skin biopsy at diagnosis.
Treatment regimens
Patients with mild cGVHD usually respond well to CsA and/or MP treatment and were excluded from this analysis. Subclinical cGVHD (evidence of cGVHD on biopsy, without clinical signs) was not treated. For those patients (n = 42) who developed cGVHD while on tapering CsA prophylaxis a further reduction of the dose was delayed and other immunosuppressive drugs were added to CsA. Thus, these patients were on varying doses of CsA when they started treatment for cGVHD: for eight patients the daily dose of CsA varied between 4 and 5 mg/kg, for 18 patients 6 and 8 mg/kg, and for 16 patients it was 10 mg/kg. The dose of CsA for the remaining three patients (two of them received MTX as GVHD prophylaxis and the other patient developed cGVHD after discontinuation of CsA prophylaxis) was 10-12 mg/kg/day. All patients with moderate or severe cGVHD were treated with a three or more drug combination as first line or salvage treatment. Eighteen patients with moderate (n = 16) or severe (n = 2) cGVHD received a three drug regimen with CsA, methylprednisolone and azathioprine (AZ) as first line therapy (CsA/MP/AZ) whereas 16 patients with moderate (n = 14) or severe (n = 2) cGVHD were given this regimen as salvage therapy (Table 2 ). These two groups of patients received MP at the dose of 1 mg/kg/day in two divided doses for the first 2 weeks then 1 mg/kg/day alternating with AZ 1.5 mg/kg/day, orally. Since 1992 we have been using more aggressive immunosuppressive treatment for patients with refractory or severe cGVHD, mainly as salvage therapy. Ten patients with moderate (n = 4) or severe (n = 6) cGVHD who failed previous therapies received salvage /day, orally. Three of these patients who were initially given the five drug regimen had discontinued MTX after 1-3 months of treatment because of neutropenia or thrombocytopenia and they therefore continued therapy with four drugs. All patients received prophylactic TMP-SMX at a dose of 5 mg/kg/day for 2 days each week. Patients received supportive care with artificial tear replacement, sun-blocking creams and parenteral nutrition as required.
Responses
Patients were re-evaluated every 1-3 months according to the severity of the disease, and a skin biopsy was performed to assess their response when considering changes in therapy. Initial response was assessed after at least 3 months of therapy. A complete response (CR) was defined as resolution of all clinical manifestations of cGVHD without signs of activity on skin biopsies. In these patients drugs were slowly tapered: first AZ and CsA, then MP were reduced. If the patient had clinically and histologically active disease after discontinuation of treatment, he was considered to have an exacerbation of cGVHD and therapy was recommenced until resolution of disease manifestations. Patients were classified as having a partial response (PR) if they had greater than 50% improvement in cGVHD symptoms in all affected organs, but not a complete response. These patients continued treatment. Patients were considered to have no response (NR) or to be refractory to treatment if cGVHD progressed after 3 months of treatment or if new organ involvement developed during immunosuppressive therapy.
Statistical analysis
The endpoints were response to treatment and survival. The probability of response and survival were estimated using the method of Kaplan and Meier. 14 Associations between response and survival and variables at presentation of cGVHD (patient age, sex, type of cGVHD, time to onset of Table 3 Results of treatment cGVHD, overall severity, platelet count, bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, type of organ involved, number of organs involved) were tested in univariate analyses using the Pearson chi-squared statistics. Variables significant at the P Ͻ 0.1 level were assessed in multiple logistic regression analyses using the GB-STAT statistical package. 15 The results were analyzed as of 31 April 2000.
Results
Clinical manifestations
All but two patients had extensive cGVHD. The two patients with limited disease had oral cGVHD. Thirty-four patients had moderate and 11 patients severe cGVHD. Seventeen patients developed progressive, 19 patients quiescent and nine patients de-novo cGVHD. Skin involvement by cGVHD was the most frequent (98%) followed by mouth (89%), eye (56%), hepatic (31%), pulmonary (31%), joint (27%), weight loss (13%), intestinal (11%), alopecia (9%), nephrotic syndrome or hemolytic anemia (9%) ( Table 1) . Ten patients (22%) had one or two organs affected, 25 patients (56%) had three or four organs affected and 10 patients (22%) had more than four organs affected by cGVHD. Median Karnofsky score (KS) or Lansky (LS) score at presentation of cGVHD was 80% (range 30-90%). Twelve of 16 patients who received the three drug regimen (CsA/MP/AZ) as salvage therapy had progression of cGVHD from mild to moderate while on previous treatment regimens.
Treatment before the multidrug combination
Eighteen patients were on tapering CsA prophylaxis only before starting the three drug regimen as first line therapy. Details of prior treatment regimens given before salvage therapy are listed in Table 3 .
Response
Overall, 77.3% of patients had a CR, 16% a PR and 6.8% failed therapy (Table 3) . Patients who received the three drug regimen as first line therapy had a higher CR (94%) than patients given this regimen as salvage treatment (88%) (P = NS). Two patients (12%) who received this combination as salvage treatment had failure while none of the patients receiving it as first line therapy experienced failure. Median durations of treatment in first line and salvage groups were 21 (range 6-59) and 31 (range 12-83) months, respectively. Most patients given the four or five drug regimens as salvage therapy had severe cGVHD and had failed previous treatments which they had followed for several years. In this group of patients, as expected, a CR rate was low (36.4%), with 55% of PR and 9% of treatment failure. Median duration of treatment in these patients was 35 (range 9-55) months. Two of these patients also received a few cycles of PUVA or extracorporeal photochemotherapy without continuous benefit. All patients with a PR continued their treatment. Patients with treatment failure were given PUVA or thalidomide along with conventional immunosuppressive drugs. The probability of CR in patients treated with the three drug regimen as first line or salvage therapy or with the four or five drug regimen was 89%, 53% and 30%, respectively. One patient had an exacerbation of cGVHD with severe sclerodermatous skin changes along with contractures after he had completed treatment with the three drug regimen. This patient is now on the five drug salvage treatment with a PR. Another patient who had a good response to the five drug salvage treatment discontinued all medications without consulting his physicians and had an exacerbation of cGVHD. Therefore, the same salvage treatment was recommenced.
Therapy-related toxicity
Overall, nine (20%) of 44 evaluable patients developed one or more of the toxicities listed in Table 3 . None of the patients who received the three drug regimen as first line therapy had toxicity, while the overall incidence of toxic complications was significantly (P = 0.052) higher in patients receiving the four or five drug combination than in patients receiving the three drug regimen as salvage therapy. One patient on the three drug regimen discontinued CsA after 5 months of treatment because of nephrotoxicity and continued treatment with AZ and MP as salvage therapy. Three patients who received the five drug regimen had neutropenia (n = 1) or thrombocytopenia (n = 2) which were resolved after withdrawal of MTX.
Infectious complications
The most frequent infectious complication was varicella zoster (27%) followed by bacterial infections with or without sepsis (6.7%) and other viral (6.6%) infectious complications (Table 3) . Eleven patients (24.4%) developed one or more episode of pneumonia which was fatal in four patients. The overall incidence of infectious complications was significantly higher in patients given the four or five drug combination than in patients receiving the three drug regimen as first or salvage therapy (100% vs 53% or vs 69%; P = 0.007 and P = 0.04, respectively).
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Mortality
Overall, nine (20%) patients died. Two out of 18 patients who received the three drug regimen as first line therapy died, one had a PR, while the other died after 2 months of treatment. Among patients who received this regimen as salvage therapy, two patients died in CR (after 1 and 2 years off therapy, respectively) and another patient died with treatment failure. One of these patients, developed carcinoma of the buccal mucosa and lower lip 2 years after he had discontinued immunosuppressive treatment having achieved a CR. Four patients who received the four drug regimen died; one in CR (who was off therapy more than 6 months), two in PR and one patient with treatment failure. None of the patients who received the five drug regimen has died. Causes of death are shown in Table 4 .
Survival and status of survivors
Overall, 36 (80%) patients have survived. Survival of patients who received the three drug regimen either as first (89%) or salvage therapy (81%) was better than of patients receiving the four or five drug regimens (63%) ( Table 5 ). The probability of survival according to treatment regimen is shown in Figure 1 . At present, 28 (78%) patients are off therapy with 100% KS or LS. Only two of eight patients who are on immunosuppressive therapy have a KS or LS Ͻ70%.
Factors associated with a complete response and survival
Univariate analyses for the entire group of patients showed that progressive onset (P = 0.038), pulmonary involvement (P = 0.030) and severe form of disease (P = 0.00001) were associated with a low CR rate, while patients who had progressive presentation of cGVHD (P = 0.007) or had a severe form (P = 0.011) of the disease had poor survivals. All variables with a P Ͻ 0.1 in univariate analyses were included in a multiple logistic regression analysis. This analysis revealed that only the severe form of disease predicted a low CR (odds ratio 0.11; 95% CI 0.11-0.96; P = 0.034) or had a negative effect on survival (odds ratio 0.32; 95% CI 0.32- 1.03; P = 0.044). All the remaining variables listed in the statistical section did not influence CR or survival.
Discussion
Despite different treatment approaches including conventional or alternative therapies many patients with chronic GVHD continue to have significantly compromised overall survival as well as quality of life. About 50% of standard risk adult patients achieve a complete response after conventional treatment with corticosteroids alone or in combination with CsA or azathioprine. 9, 10 Results of salvage regimens including CsA and prednisone or azathioprine or photochemotherapy (PUVA) or thalidomide showed low complete response rates. 16 Other salvage regimens using extracorporeal photochemotherapy, FK506, total lymphoid irradiation, mycophenolate mofetil, clofazimine, etretinate or others have had some degree of success. However, it is difficult to define the role of these agents as first line therapy for cGVHD without conventional immunosuppressive drugs. 11 Many drugs used in the past are returning to the forefront for investigation. To our knowledge, there are no published data on treatment results in cGVHD using a three or more conventional drug combination, particularly in pediatric patients. The vast majority of our patients were under 16 years of age. Our data showed the efficacy and safety of the three drug combination as first line or salvage treatment for moderate or severe cGVHD. In fact, our patients had a higher CR rate after such treatment as compared with the results obtained by other groups who used a combination of azathioprine/prednisone or CsA/prednisolone. 9, 10 Patients receiving the three drug regimen as first line or salvage treatment were comparable for severity of cGVHD and most had a moderate form of disease. It is interesting to note that patients who received the three drug regimen as first line therapy had more CRs and fewer complications than did patients receiving this combination as salvage treatment, although this difference was not significant. None of the patients who received the three drug regimen as first line therapy had failures, while two patients (12%) receiving this regimen as salvage therapy experienced treatment failure. Therefore, early institution of the three drug combination for patients with moderate cGVHD may be more effective. Most patients given the three drug regimen did not receive a uniform dose of CsA. This emphasises that benefit from a synergistic effect of combining these three drugs can occur even with low doses of CsA.
Most patients who received the four or five drug regimen had severe forms of disease and for all but one it was salvage treatment. In this group of patients the CR rate after treatment was 36.4% which is better than after the CsA/prednisone association used as salvage treatment by other authors. 16 All but one of these patients had received previous therapies for several years after transplantation and were in an advanced disease phase. The frequent infectious complications, which contributed to morbidity and mortality in this group of patients were probably related to the patient's underlying immunocompromised state as well as to the multidrug immunosuppression and may have compromised the favorable outcome of this regimen. It is possible that if the four or five drug regimen were used as first line therapy for patients with severe cGVHD, these patients would have more complete responses, better survival and fewer complications. The only patient who received the five drug regimen as first line therapy for severe cGVHD had a CR after 9 months of treatment, thus highlighting the potential benefit of this regimen when it is started early in the course of the disease.
Despite aggressive immunosuppressive treatment the incidence of treatment-related complications was not high (20%) in this study. The incidence of therapy-related toxicity was significantly higher in patients who received the four or five drug regimen than in patients receiving the three drug regimen as salvage therapy, while none of the patients receiving the latter regimen as first line therapy had such complications.
Overall incidence of infectious complications in our patients was lower than in patients treated with CsA/azathioprine or prednisone/azathioprine, 9,10 probably due to the fact that the vast majority of our patients were pediatric and did not have a pretransplant chemotherapy history which usually compromises organ function. As expected, the incidence of infectious complications was significantly higher in patients who received the four or five drug regimen as salvage therapy than in patients receiving the three drug regimen as first or salvage treatment. It is very difficult to ascertain whether this regimen or the immune suppressive effect of cGVHD contribute to the incidence of infectious complications. Infectious complications were the major causes of death in our patients highlighting the high susceptibility of this group of patients. One of our patients developed squamous cell carcinoma (two years after he had discontinued all immunosuppressive treatment given for moderate cGVHD), which was not thought to result from the three drug regimen. However, it is possible that the overall effect from the past immunosuppressive therapies as well as the cGVHD itself could have contributed to the cancer in this patient. Multiple logistic regression analyses found that only the severe form of disease was associated with a low CR rate and poor survival. Currently, 28 patients have successfully completed their treatment and are free of therapy with a KS or LS of 100%. Five patients are on tapering immunosuppression with a KS or LS of 90-100%. The remaining three patients continue treatment.
In this retrospective study we found that the three or more conventional drug combination for treatment of moderate or severe cGVHD is effective and safe at least in the nonmalignant pediatric patient population. We found an acceptable toxicity and mortality after such multidrug immunosuppression in these patients. Based on these data we recommend the use of the three drug regimen as first line therapy for moderate cGVHD, particularly in young patients. Patients with severe cGVHD can benefit from early institution of more intensive immunosuppressive treatment with the four or five drug combination. However, these results could be different in the malignant BMT setting, particularly in adult patients with compromised organ function due to previous treatments. Response and survival benefits of these multidrug regimens as first line therapy for moderate or severe cGVHD need to be examined in controlled studies.
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